利津减轻了老鼠手术后的胃
Tsukasa Nozu1,2, Saori Miyagishi3, Masatomo Ishioh3
1Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Japan.
Neurogastroenterology and motility
|August 14, 2023
概括
利津通过改善胃排空,有效治疗术后的脏 (POI). 这种化合物针对涉及POI发展的Toll-like受体4 (TLR4) 和IL-1信号通路.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 手术后阴道 (POI) 是腹部手术 (AS) 后的一种严重并发症.
- 由托尔样受体4 (TLR4) 和IL-1受体信号传递介导的肠道屏障功能受损,有助于POI.
- 利津是一种与相关的葡萄糖载体 (SGLT) 抑制剂,已知可以防止脂多糖 (LPS) 诱导的肠道屏障功能障碍.
研究的目的:
- 为了调查AS诱导的胃内膜是否由TLR4和IL-1信号传递中介.
- 为了确定弗洛里津能否改善AS诱导的胃结节.
主要方法:
- 在老鼠的腹部外科手术 (AS) 涉及结肠切除和腹腔操纵.
- 胃排空 (GE) 被评估为手术后3小时使用液体餐.
- 评估了LPS,TLR4抑制剂 (TAK-242),IL-1受体对抗剂 (anakinra) 和phlorizin的作用.
主要成果:
- AS显著延迟了GE,这种效果被TAK-242和anakinra阻止了.
- 此外,LPS还通过TLR4和IL-1受体通路延迟了GE.
- 皮下施用弗洛里津在AS和LPS模型中显著改善了延迟GE,这种效果被林受体对抗剂阻断.
结论:
- 由AS诱导的胃内膜是通过TLR4和IL-1信号传递进行的,类似于LPS效应.
- 利津可以改善胃,可能是通过激林信号激活,也可能是通过SGLT2抑制.
- 利津证明了作为治疗POI的治疗剂的潜力.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
308
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
308
Drugs for Treatment of Constipation-Predominant IBS
210
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
210
Intestinal Phase of Digestion
5.2K
The intestinal phase of digestion is the third and final stage of the digestive process, occurring after the cephalic and gastric phases. It begins when chyme, a partially digested mixture of food and digestive enzymes, enters the small intestine from the stomach. This phase is crucial for nutrient absorption and involves complex hormonal and enzymatic interactions.
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
5.2K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
247
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
247
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
243
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
243
Drugs for Treatment of Diarrhea-Predominant IBS
213
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
213


